دورية أكاديمية
Polypill Eligibility for Patients with Heart Failure with Reduced Ejection Fraction in the ASIAN-HF Registry: A Cross-Sectional Analysis
| العنوان: | Polypill Eligibility for Patients with Heart Failure with Reduced Ejection Fraction in the ASIAN-HF Registry: A Cross-Sectional Analysis |
|---|---|
| المؤلفون: | Aishwarya Vijay, Wan Ting Tay, Tiew-Hwa K. Teng, Kanako Teramoto, Jasper Tromp, Wouter Ouwerkerk, Seet Yoong Lo, Wataru Shimizu, Mark D. Huffman, Carolyn S. P. Lam, Chanchal Chandramouli, Anubha Agarwal |
| المصدر: | Global Heart, Vol 18, Iss 1, Pp 33-33 (2023) |
| بيانات النشر: | Ubiquity Press, 2023. |
| سنة النشر: | 2023 |
| المجموعة: | LCC:Diseases of the circulatory (Cardiovascular) system LCC:Public aspects of medicine |
| مصطلحات موضوعية: | polypill, hfref, global cardiovascular health, asian-hf, guideline-directed medical therapy, Diseases of the circulatory (Cardiovascular) system, RC666-701, Public aspects of medicine, RA1-1270 |
| الوصف: | Background: The rates of guideline-directed medical therapy (GDMT) prescription for heart failure with reduced ejection fraction (HFrEF) in Asia remain sub-optimal. The primary objective of this study was to examine HFrEF polypill eligibility in the context of measured baseline prescription rates of individual components of GDMT among participants with HFrEF in Asia. Methods: A retrospective analysis of 4,868 patients with HFrEF from the multi-national ASIAN-HF registry was performed, and 3,716 patients were included in the final, complete case analysis. Eligibility for a HFrEF polypill, upon which patients were grouped and characterized, was based on the following: left ventricular systolic dysfunction (LVEF < 40% on baseline echocardiography), systolic blood pressure ≥ 100 mm Hg, heart rate ≥ 50 beats/minute, eGFR ≥ 30 mL/min/1.73 m, and serum potassium ≤ 5.0 mEq/L. Regression analyses were performed to evaluate associations of the baseline sociodemographic factors with HFrEF polypill eligibility. Results: Among 3,716 patients with HFrEF in the ASIAN-HF registry, 70.3% were eligible for a HFrEF polypill. HFrEF polypill eligibility was significantly higher than baseline rates of triple therapy prescription of GDMT across sex, all studied geographical regions, and income levels. Patients were more likely to be eligible for a HFrEF polypill if they were younger and male, with higher BMI and systolic blood pressure, and less likely to be eligible if they were from Japan and Thailand. Conclusion: The majority of patients with HFrEF in ASIAN-HF were eligible for a HFrEF polypill and were not receiving conventional triple therapy. HFrEF polypills may be a feasible and scalable implementation strategy to help close the treatment gap among patients with HFrEF in Asia. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 2211-8179 |
| العلاقة: | https://account.globalheartjournal.com/index.php/up-j-gh/article/view/1215Test; https://doaj.org/toc/2211-8179Test |
| DOI: | 10.5334/gh.1215 |
| الوصول الحر: | https://doaj.org/article/e959dab081e2405d84329ea4dd38377eTest |
| رقم الانضمام: | edsdoj.959dab081e2405d84329ea4dd38377e |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 22118179 |
|---|---|
| DOI: | 10.5334/gh.1215 |